SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells.

doi:10.1093/hmg/ddx218

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells.

Human molecular genetics - 1 Sept 2017

Vianello Sara, Pantic Boris, Fusto Aurora, Bello Luca, Galletta Eva, Borgia Doriana, Gavassini Bruno F, Semplicini Claudio, Sorarù Gianni, Vitiello Libero, Pegoraro Elena

Abstract excerpt

Glucocorticoids are beneficial in Duchenne muscular dystrophy (DMD). Osteopontin (OPN), the protein product of SPP1, plays a role in DMD pathology modulating muscle inflammation and regeneration. A polymorphism in the SPP1 promoter (rs28357094) has been recognized as a genetic modifier of DMD, and there is evidence suggesting that it modifies response to glucocorticoid treatment. The effect of the glucocorticoid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Culture Techniques

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, Modifier

Share to Glucocorticoids

Share to Muscle Fibers, Skeletal

Share to Muscle, Skeletal

Share to Muscular Dystrophy, Duchenne

Share to Myoblasts

Share to Osteopontin

Source

Open in PubMed

Identifiers

PMID: 28595270
DOI: 10.1093/hmg/ddx218

Genes

DMD
SPP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells.PMID 28595270Read ↗

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy.Semantic proximity Read ↗

TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle.Semantic proximity Read ↗

Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy.Semantic proximity Read ↗

The “Usual Suspects”: Genes for Inflammation, Fibrosis, Regeneration, and Muscle Strength Modify Duchenne Muscular DystrophySemantic proximity Read ↗

Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy.Semantic proximity Read ↗

LTBP4, SPP1, and CD40 Variants: Genetic Modifiers of Duchenne Muscular Dystrophy Analyzed in Serbian Patients.Semantic proximity Read ↗

Alterations in osteopontin modify muscle size in females in both humans and mice.Semantic proximity Read ↗

C–X–C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophySemantic proximity Read ↗

Modifier genes and their effect on Duchenne muscular dystrophySemantic proximity Read ↗

Dual effect of a single nucleotide polymorphism in the first intron of the porcine secreted phosphoprotein 1 gene: allele-specific binding of C/EBP beta and activation of aberrant splicing.Semantic proximity Read ↗

Is it time for genetic modifiers to predict prognosis in Duchenne muscular dystrophy?Semantic proximity Read ↗

Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.